Annual CCA Summit Is Now a Key Scientific Meeting in BTCs

December 2023, Vol 4, No 4
Milind M. Javle, MD
Hubert L. and Olive Stringer Professor
GI Medical Oncology
University of Texas MD Anderson
Cancer Center, Houston
Chair, NCI Task Force,
Hepatobiliary Cancers

Dear Readers,

The 5th annual CCA Summit, held October 19-21, 2023, in Scottsdale, AZ, was a very successful meeting by all measures, and the summit has gradually become one of the key scientific meetings in biliary tract cancers (BTCs). This year’s summit was chaired by Flavio Rocha, MD, FACP, Oregon Health & Science University, Portland, OR, and the meeting presented key highlights in surgical, medical, and radiation oncology from the leaders in the field.

As always, the meeting included discussions of novel therapies, including targeted agents presented by Vaibhav Sahai, MBBS, MS, Midhun Malla, MD, MS, and Milind Javle, MD; antibody–drug conjugates by Renuka Iyer, MD; novel immunotherapies, including cell-based therapies, by Cassian Yee, MD; HER2/neu-directed therapies by Shubham Pant, MD, MBBS; and vaccines by Nilofer Azad, MD. These presentations set the theme for the meeting.

Multimodal therapies, which are critical for the successful management of cholangiocarcinoma (CCA), include radioembolization and stereotactic radiotherapy, and both are now being combined with immune checkpoint inhibitors. A key presentation on the surgical management of these tumors, provided by William Jarnagin, MD, FACS, was followed by an insightful session on the pros and cons of neoadjuvant therapy by Cristina Ferrone, MD, FACS. The surgeons participating in the summit highlighted that surgery is potentially curative; however, the addition of multimodal approaches augments the likelihood of long-term disease control.

The annual summit is increasingly focused on translational science, with important presentations on immunotherapy biomarkers by Greg Lesinski, PhD, MPH, and in vivo models by Rory Smoot, MD, and Larry Kwong, PhD.

In the concluding sessions, Bruce Lin, MD, and Kristen Spencer, DO, MPH, underscored the emerging role of biomarkers in CCA management. Novel radiologic methods for the management of locally advanced and surgically resectable CCA were discussed by Eugene Koay, MD, PhD, and Mike Choti, MD, MBA, FACS.

Finally, we all congratulate Paige Griffith, CRNP, for winning the CCA ONE Award as well as the other nominees, Kirsten Hernandez, BSN, RN, and Bobbie Khan, MS, RN, OCN, for their wonderful work.

Congratulations to all participants for a very successful summit. Mark your calendars for the next CCA Summit on October 17-19, 2024, in Lost Pines, TX!

Sincerely,

Milind M. Javle, MD

Related Items

Advancing Care for Cholangiocarcinoma: Highlights From the 7th Annual Cholangiocarcinoma Summit
By Milind M. Javle, MD
December 2025, Vol 6, No 4
Welcome to the final edition of CCA News for this season. This end-of-season issue reflects highlights from the 2025 Cholangiocarcinoma (CCA) Summit held in Scottsdale, AZ, where international experts presented leading advances in CCA.
Advancing Cholangiocarcinoma Care: Breakthroughs in Targeted Therapies, Immunotherapy, and Early Detection
By Milind M. Javle, MD
September 2025, Vol 6, No 3
Groundbreaking advancements in cholangiocarcinoma research, including targeted therapies, immunotherapy innovations, and promising early detection strategies, are highlighted in this issue.
Advancing Hope: Insights From the 12th Annual Cholangiocarcinoma Foundation Conference
By Milind M. Javle, MD
June 2025, Vol 6, No 2
Explore pivotal advancements in research, care strategies, and collaborative efforts shared at the 12th Annual Cholangiocarcinoma Foundation Conference, shaping the future of cholangiocarcinoma treatment.
Presentations From 2025 ASCO GI Cancers Symposium Show Advancements in BTC Research
By Milind M. Javle, MD
March 2025, Vol 6, No 1
The 2025 ASCO GI Cancers Symposium on biliary tract cancer (BTC) emphasized significant research findings, particularly the relevance of mutational subsets, the role of personalized medicine, and the impact of multidisciplinary therapies on enhancing outcomes for patients with BTC.
The Annual CCA Summit Has Emerged as a Significant Scientific Conference Within the Realm of BTCs
By Milind M. Javle, MD
December 2024, Vol 5, No 4
The 6th Annual CCA Summit featured presentations and discussions on novel therapies, surgical approaches, locoregional therapies, the use of ctDNA monitoring, treatment options for localized multifocal intrahepatic cholangiocarcinoma, the role of consolidative radiotherapy, and advancements in artificial intelligence for CCA.
Presentations From ASCO Showcase Advances in the Management of Patients With Biliary Tract Cancer
By Milind M. Javle, MD
September 2024, Vol 5, No 3
We are highlighting several key areas of clinical research in this issue of CCA News. The role of radiation therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) has been established in single-arm phase 2 trials; however, there is a lack of randomized controlled data.
Notable Takeaways From the 2024 Cholangiocarcinoma Foundation Annual Conference
By Milind M. Javle, MD
June 2024, Vol 5, No 2
Editor-in-Chief Milind M. Javle, MD, highlights takeaways from the 2024 Cholangiocarcinoma (CCA) Foundation Annual Conference.
ASCO GI Presentations Show Progress in BTC
By Milind M. Javle, MD
March 2024, Vol 5, No 1
Editor-in-Chief Milind M. Javle, MD, highlights takeaways from the ASCO GI 2024 symposium, emphasizing the latest developments in biliary tract cancer.
Advances in the Management of Patients With Biliary Cancer
By Milind M. Javle, MD
September 2023, Vol 4, No 3
As we approach the fall season, it is wonderful to reflect on some of the amazing research presented this year, most recently at the ASCO 2023 annual meeting. One of the major highlights of ASCO this year included the results of HER2/neu-directed novel therapies in biliary cancer. Shubham Pant, MD, MBBS, from MD Anderson Cancer Center, presented the results of the HERIZON-1 clinical trial of the bispecific antibody zanidatamab in HER2/neu-expressing biliary cancers.
Annual CCF Conference Brings Together All Stakeholders
By Milind M. Javle, MD
June 2023, Vol 4, No 2
This issue of CCA News highlights the Cholangiocarcinoma Foundation (CCF) 10th Annual Conference held in April. This meeting was chaired by Dr Chiara Branconi, a Lord Kelvin Adam Smith Reader at the University of Glasgow and a medical oncologist with Beatson Cancer Centre; and Dr Laura Goff, medical director of the Vanderbilt-Ingram Cancer Center’s Hematology and Oncology Division.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Profession or Role
Primary Specialty or Disease State